Patents by Inventor Stefan Sperl

Stefan Sperl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective inhibitors of the urokinase plasminogen activator
    Patent number: 7208521
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: April 24, 2007
    Assignee: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jörg Stürzebecher, Olaf Wilhelm
  • Arginine mimetics as factor Xa inhibitors
    Publication number: 20060189689
    Abstract: The invention relates generally to a novel type of arginine mimetics which are inhibitors of factor Xa; to pharmaceutical compositions which comprise these mimetics; and to the use of these arginine mimetics for producing compositions for antithrombotic therapy.
    Type: Application
    Filed: April 10, 2006
    Publication date: August 24, 2006
    Applicant: Wilex AG
    Inventors: Luis Moroder, Stefan Sperl, Jorg Sturzebecher
  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Publication number: 20060142305
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: November 28, 2005
    Publication date: June 29, 2006
    Applicant: WILEX AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Highly selective inhibitors of the urokinase plasminogen activator
    Patent number: 7049344
    Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: May 23, 2006
    Assignees: Wilex Biotechnology GmbH, Max-Planck-Gessellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
  • Selective inhibitors of the urokinase plasminogen activator
    Patent number: 7049460
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC 3.4.21.31) of the aryl guanidine type.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: May 23, 2006
    Assignee: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jörg Stürzebecher, Olaf Wilhelm
  • Arginine mimetics as factor Xinhibitors
    Patent number: 7038074
    Abstract: The invention relates generally to a novel type of arginine mimetics which are inhibitors of factor Xa; to pharmaceutical compositions which comprise these mimetics; and to the use of these arginine mimetics for producing compositions for antithrombotic therapy.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: May 2, 2006
    Assignee: Wilex AG
    Inventors: Luis Moroder, Stefan Sperl, Jörg Stürzebecher
  • Guanidino phenylalanin compounds used as urokinase inhibitors
    Publication number: 20050267127
    Abstract: The invention relates to the use of derivatives of 3-guanidinophenylalanine as urokinase inhibitors for treating malignant tumors and metastasis.
    Type: Application
    Filed: June 5, 2003
    Publication date: December 1, 2005
    Applicant: Wilex AG
    Inventor: Stefan Sperl
  • Method for the production of phenylalanine derivatives
    Publication number: 20050245757
    Abstract: The invention relates to an improved method for the production of 3-amidino- or 3-guanidinophenylalanine derivatives, especially triisopropylphenyl-sulfonyl-substituted 3-amidino- or 3-guanidinophenylalanine derivatives.
    Type: Application
    Filed: July 25, 2003
    Publication date: November 3, 2005
    Inventors: Katja Wosikowski-Buters, Stefan Sperl, Joachim Sommer
  • Selective inhibitors of the urokinase plasminogen activator
    Publication number: 20050215642
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.
    Type: Application
    Filed: February 16, 2005
    Publication date: September 29, 2005
    Applicant: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jorg Sturzebecher, Olaf Wilhelm
  • Highly selective inhibitors of the urokinase plasminogen activator
    Publication number: 20050119348
    Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.
    Type: Application
    Filed: November 22, 2004
    Publication date: June 2, 2005
    Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
  • Highly selective inhibitors of the urokinase plasminogen activator
    Patent number: 6841702
    Abstract: The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: January 11, 2005
    Assignees: Wilex Biotechnology GmbH, Max-Planck-Gesellschaft zur Forderung der Wissenschaften EV
    Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
  • Selective urokinase inhibitors
    Publication number: 20040266766
    Abstract: The present invention concerns new selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31) and their use as therapeutic agents for treating urokinase-associated diseases such as malignant tumors and the formation of metastases.
    Type: Application
    Filed: June 14, 2004
    Publication date: December 30, 2004
    Applicant: Wilex AG
    Inventor: Stefan Sperl